Matinas BioPharma Holdings (MTNB) Income from Continuing Operations (2014 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Income from Continuing Operations of 1944000.0 for Q1 2026, up 1.07% year-over-year from 1923444.11 in Q1 2025, and down 13.55% quarter-over-quarter from 1712000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Income from Continuing Operations for 13 consecutive years, with 1944000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 1.07% year-over-year to 1944000.0; the TTM figure through Mar 2026 stood at 7616000.0 (up 70.14% YoY), while the FY2025 annual figure was 10345000.0, up 57.34% from the prior year.
- Income from Continuing Operations fell to 1944000.0 in Q1 2026 per MTNB's latest filing, from 1712000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1712000.0 in Q4 2025 and bottomed at 39868000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 8094823.53 across 5 years, with a median of 6846000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 107.67% — and 2023, when it jumped 85.23%.
- Matinas BioPharma Holdings' Income from Continuing Operations stood at 39868000.0 in 2022, then surged by 85.23% to 5888000.0 in 2023, then tumbled by 44.36% to 8500000.0 in 2024, then soared by 79.86% to 1712000.0 in 2025, then decreased by 13.55% to 1944000.0 in 2026.
- Business Quant data shows MTNB's Income from Continuing Operations at 1944000.0 in Q1 2026, 1712000.0 in Q4 2025, and 1850000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | -1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.56 Mn |
| Mar 31, 2026 | -1.94 Mn |
| Dec 31, 2025 | -1.71 Mn |
| Sep 30, 2025 | -1.85 Mn |
| Jun 30, 2025 | -2.11 Mn |
| Mar 31, 2025 | -1.97 Mn |
| Dec 31, 2024 | -8.50 Mn |
| Sep 30, 2024 | -5.33 Mn |
| Jun 30, 2024 | -9.72 Mn |
| Mar 31, 2024 | -6.85 Mn |
| Dec 31, 2023 | -5.89 Mn |
| Sep 30, 2023 | -7.17 Mn |
| Jun 30, 2023 | -7.20 Mn |
| Mar 31, 2023 | -6.66 Mn |
| Dec 31, 2022 | -39.87 Mn |
| Sep 30, 2022 | -10.95 Mn |
| Jun 30, 2022 | -11.42 Mn |
| Mar 31, 2022 | -8.48 Mn |
| Dec 31, 2021 | -37.74 Mn |
| Sep 30, 2021 | -13.02 Mn |